# KEYNOTE-146 (NCT02501096)

> A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02501096
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Eisai Inc.
- Conditions: Tumors
- Interventions: Lenvatinib; Pembrolizumab
- Enrollment: 357
- Primary outcome: Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib
- Primary outcome: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib
- Primary outcome: Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24

## Indexed commentary on KEYNOTE-146 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 5
- YouTube: 4
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-146-nct02501096

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02501096", "email": "<work email>"}; the inbox owner confirms by the emailed link.